The Specimen Acquisition and Pathology Core is a key component of the SPORE and will support the translational goals of SPORE Projects, as well as developmental projects funded through the SPORE. Dr. Porter's leadership will provide not only research and clinical breast pathology expertise but also integration of Core B activities with the SPORE overall, and developmental projects in particular. This coordination of specimen acquisition and distribution with promotion of new research will greatly aid translation of basic discoveries into experiments involving human samples. The Core augments the existing robust FHCRC/UW Cancer Consortium Breast Specimen Repository and Registry (BSRR) and will function to centralize specimen acquisition, processing, pathologic analysis and distribution of samples needed by SPORE projects. It will also provide a laboratory base for select biomarker assays in support of the major and developmental projects. Specifically the Core will: 1) Use the established and efficient BSRR to procure and distribute tissue and blood specimens for SPORE and developmental projects 2) Perform protocol-specific specimen processing for SPORE and developmental projects 3) Maintain a database that allows specimen tracking and distribution, linkage with relevant deidentified data, and data sharing with other projects and cores 4) Provide high-quality pathology support for SPORE and developmental projects including: ? Pathology review of tissues at various levels of complexity ? Histology sectioning and preparation of section slides for histologic evaluation ? Immunohistochemistry (IHC), and new antibody work-up and optimization ? IHC interpretation of both immunoperoxidase and immunofluorescence stains ? Laser capture microdissection (LCM) ? Tissue microarray (TMA) design, construction, sectioning, and imaging

Public Health Relevance

The Specimen Acquisition and Pathology Core is a key component of the SPORE and will support the translational goals of the projects and developmental projects. The core will take full advantage of institutional resources, integrate them for efficient use by SPORE investigators, and flexibly adapt to needs and new developmental projects during the time frame of the SPORE grant.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA138293-04
Application #
8543571
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
4
Fiscal Year
2013
Total Cost
$214,957
Indirect Cost
$83,987
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
O'Sullivan, Finbarr; O'Sullivan, Janet N; Huang, Jian et al. (2018) Assessment of a statistical AIF extraction method for dynamic PET studies with 15O water and 18F fluorodeoxyglucose in locally advanced breast cancer patients. J Med Imaging (Bellingham) 5:011010
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Amornsiripanitch, Nita; Nguyen, Vicky T; Rahbar, Habib et al. (2018) Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers. J Magn Reson Imaging 48:226-236
Balakrishnan, Ashwini; Goodpaster, Tracy; Randolph-Habecker, Julie et al. (2017) Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. Clin Cancer Res 23:3061-3071
Wangerin, Kristen A; Muzi, Mark; Peterson, Lanell M et al. (2017) A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy. Phys Med Biol 62:3639-3655
Rahbar, Habib; McDonald, Elizabeth S; Lee, Janie M et al. (2016) How Can Advanced Imaging Be Used to Mitigate Potential Breast Cancer Overdiagnosis? Acad Radiol 23:768-73
Sommermeyer, D; Hudecek, M; Kosasih, P L et al. (2016) Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30:492-500
Liu, Lingfeng; Sommermeyer, Daniel; Cabanov, Alexandra et al. (2016) Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy. Nat Biotechnol 34:430-4
Rahbar, Habib; Partridge, Savannah C (2016) Multiparametric MR Imaging of Breast Cancer. Magn Reson Imaging Clin N Am 24:223-238
Rahbar, Habib; Parsian, Sana; Lam, Diana L et al. (2016) Can MRI biomarkers at 3 T identify low-risk ductal carcinoma in situ? Clin Imaging 40:125-9

Showing the most recent 10 out of 54 publications